[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Nonoshita T, Shioyama Y, Nakamura K, Nakashima T, Ohga S, Yoshitake T, Ohnishi K, Terashima K, Asai K, Honda H: Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma. J Radiat Res; 2010;51(4):481-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.
  • In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma.
  • A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1.
  • Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy.
  • S-1 was administered 65 mg/m(2) per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy.
  • Chemoradiotherapy with S-1 was feasible, well tolerated and effective.
  • This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Glottis. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Radiation-Sensitizing Agents / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601829.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Radiation-Sensitizing Agents; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; UA8SE1325T / gimeracil
  •  go-up   go-down


2. Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol; 2010 Jul 30;2:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.
  • BACKGROUND: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC) who were treated by radiotherapy (RT) with or without chemotherapy.
  • METHODS: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001 and 2006 were analyzed retrospectively.
  • Of the 58 patients, eight developed recurrent disease at the primary site, and one had lymph node recurrences on the neck.
  • Only two patients died of laryngeal carcinoma, and one died of intercurrent disease.
  • CONCLUSIONS: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2 GC by means of RT with or without chemotherapy.
  • There was, however, no statistical difference in LC rates for the two types of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):21-6 [10656367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1104-9 [18950960.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):415-9 [11872287.001]
  • [Cites] Head Neck. 2002 Jul;24(7):637-42 [12112536.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):472-5 [12115532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):471-8 [12243824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):313-7 [3104243.001]
  • [Cites] Radiother Oncol. 1998 May;47(2):161-6 [9683364.001]
  • [Cites] Laryngoscope. 1998 Dec;108(12):1853-5 [9851503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86 [16095847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82 [16169681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):995-1001 [16406396.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Radiat Med. 2006 May;24(4):277-81 [16958401.001]
  • [Cites] Oncology. 2006;71(5-6):369-73 [17851262.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3497-500 [17972507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94 [17869013.001]
  • [Cites] Auris Nasus Larynx. 2008 Jun;35(2):213-9 [17996416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • (PMID = 20673360.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2919535
  •  go-up   go-down


3. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


Advertisement
4. Dornfeld K, Hopkins S, Simmons J, Spitz DR, Menda Y, Graham M, Smith R, Funk G, Karnell L, Karnell M, Dornfeld M, Yao M, Buatti J: Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2008 Jun 1;71(2):386-92
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy.
  • PURPOSE: Inflammation and increased metabolic activity associated with oxidative stress in irradiated normal tissues may contribute to both complications following radiotherapy and increased glucose uptake as detected by posttherapy fluorodeoxyglucose (FDG)-PET imaging.
  • We sought to determine whether increased glucose uptake in normal tissues after chemoradiotherapy is associated with increased toxicity.
  • METHODS AND MATERIALS: Consecutive patients with locoregionally advanced head and neck cancers treated with intensity-modulated radiation therapy and free of recurrence at 1 year were studied.
  • Functional outcome was measured using a quality of life questionnaire and weight loss and type of diet tolerated 1 year after therapy.
  • RESULTS: Standardized uptake value levels in the supraglottic and glottic larynx from FDG-PET imaging obtained 12 months posttreatment were inversely associated with quality of life measures and were correlated with a more restricted diet 1 year after therapy.
  • SUV levels at 3 months after therapy did not correlate with functional outcome.
  • Increases in SUV levels in normal tissues between 3 and 12 months were commonly found in the absence of recurrence.
  • CONCLUSION: Altered metabolism in irradiated tissues persists 1 year after therapy.
  • FDG-PET scans may be used to assess normal tissue damage following chemoradiotherapy.
  • These data support investigating hypermetabolic conditions associated with either inflammation, oxidative stress, or both, as causal agents for radiation-induced normal tissue damage.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):702-13 [16929324.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Biochem Soc Trans. 2006 Nov;34(Pt 5):965-70 [17052238.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10377-83 [17079457.001]
  • [Cites] Cytokine. 2006 Aug;35(3-4):186-92 [16979900.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):750-7 [17418971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1030-5 [17398033.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):1-12 [10758302.001]
  • [Cites] Arch Biochem Biophys. 2001 Aug 1;392(1):103-9 [11469800.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1920-4 [11801970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Radiother Oncol. 2002 May;63(2):129-45 [12063002.001]
  • [Cites] Head Neck. 2003 Jul;25(7):561-75 [12808660.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):825-9 [15262758.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):412-8 [15380574.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(4):671-5 [1544835.001]
  • [Cites] Head Neck. 1993 Mar-Apr;15(2):87-96 [8440619.001]
  • [Cites] Arch Biochem Biophys. 1994 Jul;312(1):52-8 [8031146.001]
  • [Cites] Am J Physiol. 1995 Jan;268(1 Pt 1):C227-36 [7840152.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1157-66 [8822723.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29294-302 [10506188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Radiographics. 2005 Sep-Oct;25(5):1357-68 [16160116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21 [16168834.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Oct;131(10):879-85 [16230590.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):455-9 [16500444.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2636-43 [16763277.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):845-51 [17011456.001]
  • (PMID = 18164842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1K08CA111404-01A1; United States / NCI NIH HHS / CA / K08 CA111404-01A1; United States / NCI NIH HHS / CA / CA104219-01; United States / NCI NIH HHS / CA / R01 CA106908; United States / NCI NIH HHS / CA / R01 CA106908-01; United States / NCI NIH HHS / CA / K08 CA111404; United States / NCI NIH HHS / CA / CA111404-01A1; United States / NCI NIH HHS / CA / R01 CA106908-03; United States / NCI NIH HHS / CA / L30 CA104219-01; United States / NCI NIH HHS / CA / CA106908-03; United States / NCI NIH HHS / CA / CA106908-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ NIHMS50622; NLM/ PMC2699674
  •  go-up   go-down


5. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans.
  • Thirteen patients (42%) received concurrent chemotherapy during IMRT.
  • Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.
  • CONCLUSIONS: In the context of glottic laryngeal shielding, we describe candidate oral cavity and superior pharyngeal constrictor organs at risk and dose-volume constraints associated with preserved long-term swallowing function; these constraints are currently undergoing prospective validation.
  • Strict protection of the glottic larynx via beam-split IMRT techniques promises to make chronic aspiration an uncommon outcome.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


6. Yoo SS, Carter D, Turner BC, Sasaki CT, Son YH, Wilson LD, Glazer PM, Haffty BG: Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer; 2000 Feb 20;90(1):22-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the current study is to evaluate the prognostic significance of cycD1 for local recurrence in early-stage larynx cancer treated with primary radiation therapy.
  • All patients had squamous cell carcinoma of the larynx and were treated with primary radiation to a total median dose of 66 Gy in daily fractions of 2 Gy, without surgery or chemotherapy.
  • Thirty patients who suffered a local relapse in the larynx after treatment served as the index case population.
  • These 30 cases were matched by age, sex, site (glottic vs. supraglottic), radiation therapy technique/dose, and follow-up, to 30 control patients who did not experience a local relapse.
  • CycD1 levels correlated with proliferating cell nuclear antigen levels.
  • These data suggest that low levels of cycD1 correlate with relatively radioresistant early-stage larynx carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Cyclin D1 / analysis. Laryngeal Neoplasms / chemistry. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry
  • [MeSH-minor] Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10725854.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


7. Almadori G, Bussu F, Navarra P, Galli J, Paludetti G, Giardina B, Maurizi M: Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer; 2006 Jul 15;107(2):328-36
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia.
  • BACKGROUND: It has been previously observed that patients with head and neck squamous cell carcinoma or with laryngeal leucoplakia present a significant reduction in plasma folate levels.
  • The current Phase IIA pilot study assessed the effectiveness of folic acid as a chemopreventive agent in patients affected by glottic laryngeal leucoplakia.
  • METHODS: Forty-three untreated patients affected by glottic laryngeal leucoplakia were enrolled in the Ear, Nose, and Throat Department (Universita Cattolica del Saco Cuore, Rome, Italy).
  • Glottic leucoplakia was initially diagnosed by indirect laryngoscopy and successively confirmed by diagnostic direct microlaryngoscopy with a biopsy for histologic assessment.
  • [MeSH-major] Folic Acid / therapeutic use. Laryngeal Neoplasms / drug therapy. Leukoplakia / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Laryngoscopy. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770770.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


8. Nonoshita T, Shioyama Y, Kunitake N, Nakamura K, Nomoto S, Ohga S, Toriya Y, Ono M, Honda H: Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Fukuoka Igaku Zasshi; 2009 Jan;100(1):26-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.
  • This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.
  • Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation.
  • Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy).
  • The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients.
  • Twenty-four patients received adjuvant chemotherapy with tegafur and uracil.
  • Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038).
  • The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82% and 42%, respectively.
  • No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis.
  • We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy.
  • Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control.
  • We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378773.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Vachin F, Hans S, Atlan D, Brasnu D, Menard M, Laccourreye O: [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy]. Ann Otolaryngol Chir Cervicofac; 2004 Jun;121(3):140-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy].
  • [Transliterated title] Résultats à long-terme de la chimiothérapie exclusive des cancers épidermoïdes glottiques.
  • OBJECTIVES: To evaluate the long-term results of exclusive chemotherapy for T1-T3N0M0 glottic squamous cell carcinoma complete clinical responders after induction chemotherapy.
  • MATERIAL AND METHODS: Between 1985 and 2000, 69 patients with glottic squamous cell carcinoma complete clinical responders after induction chemotherapy were managed with exclusive chemotherapy at our department.
  • Chemotherapy associated platinum and fluorouracil.
  • This retrospective analysis evaluated actuarial survival, treatment morbidity, oncologic events and laryngeal preservation.
  • Chemotherapy never resulted in death.
  • CONCLUSION: Altogether our data and the review of the literature suggest that in patients achieving a complete clinical response after and induction based chemotherapy regimen, the completion of an exclusive chemotherapy regimen appears to be a valid alternative to the conventional use of radiotherapy or chemo-radiation protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15223999.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Scheuermann K, Delank KW: [Perforation of the esophagus with a mediastinal abscess]. HNO; 2005 Jan;53(1):66-70
MedlinePlus Health Information. consumer health - Abscess.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Osophagusperforation mit Mediastinalabszess. Eine Spätkomplikation der chirurgischen Stimmrehabilitation nach Laryngektomie.
  • CASE REPORT: The 69 year old patient underwent laryngectomy, selective bilateral neck dissection and the implantation of a Provox voice prosthesis because of a glottic squamous cell carcinoma (pT(4), pN(0), M(0)).
  • During adjuvant radiochemotherapy, the patient developed distinctive cervical edema which led to a tilting of the Provox prosthesis.
  • Due to a perforation of the posterior esophageal wall, the patient developed a pronounced mediastinal abscess which was relieved through a transcervical mediastinotomy.
  • Antibiotic therapy led to a partial remission of the symptoms.
  • In particular, when the tissue is injured during the course of radiotherapy, this type of complication should be taken into consideration.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Bacterial Infections / drug therapy. Bacterial Infections / etiology. Bacterial Infections / surgery. Humans. Male. Prosthesis Failure. Treatment Outcome. Voice Disorders / rehabilitation. Voice Disorders / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Otorhinolaryngol. 2001 May;258(4):173-6 [11407448.001]
  • [Cites] Laryngorhinootologie. 2002 Dec;81(12):890-3 [12486628.001]
  • [Cites] Laryngoscope. 1989 May;99(5):489-91 [2709936.001]
  • [Cites] Laryngorhinootologie. 1994 Feb;73(2):84-7 [8161415.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Sep;116(9):1074-6 [2116810.001]
  • [Cites] HNO. 1995 Mar;43(3):197-201 [7759304.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):762-3 [2115667.001]
  • [Cites] Laryngoscope. 1997 Apr;107(4):527-30 [9111385.001]
  • [Cites] Otolaryngol Head Neck Surg. 1985 Dec;93(6):809-11 [3937107.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Nov;126(11):1320-8 [11074828.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1988 Sep-Oct;97(5 Pt 1):537-41 [3178106.001]
  • [Cites] HNO. 1994 Feb;42(2):99-103 [8163402.001]
  • [Cites] Laryngoscope. 1985 Nov;95(11):1360-2 [4058216.001]
  • [Cites] HNO. 2000 Jul;48(7):508-16 [10955228.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1202-7 [2233085.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Aug;120(8):840-5 [8049046.001]
  • [Cites] Am J Otolaryngol. 1990 Mar-Apr;11(2):85-9 [2344000.001]
  • [Cites] HNO. 1990 Nov;38(11):417-20 [2289900.001]
  • [Cites] Laryngoscope. 1987 May;97(5):562-7 [3573901.001]
  • (PMID = 15064925.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


11. Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):461-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy.
  • PURPOSE: To report the treatment outcomes of definitive radiotherapy (RT) for early-stage squamous cell carcinoma (SCCA) of the glottic larynx.
  • METHODS AND MATERIALS: We retrospectively reviewed the medical records of 585 patients with T1N0 to T2N0 invasive SCCA of the glottic larynx treated between 1964 and 2006 with RT alone.
  • None of these patients received chemotherapy or had elective nodal RT.
  • Multivariate analysis revealed that overall treatment time greater than 41 days (p = 0.001) and poorly differentiated histology (p = 0.016) adversely affected LC.
  • CONCLUSION: Based on our study results, RT cures a high proportion of patients with T1N0 to T2N0 glottic SCCAs and has a low rate of severe complications.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Glottis / pathology. Glottis / surgery. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Radiation Injuries / complications. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20153124.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H: Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol; 2006 Jun;120(6):478-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx.
  • This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx.
  • Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66-72 Gy.
  • Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563197.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Ikeda Y, Tsukuda M, Tanigaki Y, Yabuki K, Mitake D, Ishitoya J: [Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma]. Gan To Kagaku Ryoho; 2008 May;35(5):789-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma].
  • Early glottic carcinoma has a good prognosis compared to other head and neck carcinomas, but we must aim for larynx preservation in the treatment.
  • However for T2N0, the treatment strategies differ in each institution, and larynx preservation rates range from 72% to 85%, and are not high enough.
  • We conducted a study to determine the efficacy of the concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma.
  • In this study, 12 patients with T2N0 glottic type laryngeal squamous cell carcinoma enrolled from the year 2004 to 2006, received one reduction dose of S-1 (80 or 100 mg/day) with concomitant irradiation with a total dose of 60-70 Gy (2.0 Gy/fr).
  • The 2-week administration of S-1 followed by one-week rest was repeated during irradiation.
  • In terms of adverse events of Grade 3 and above, Grade 3 mucositis and dermatitis were found in 2 patients each, but there was no cancellation nor interruption of S-1 or irradiation.
  • All patients achieved pathological CR at the time of evaluation after the primary treatment, and no recurrences have been seen yet in any of the primary sites.
  • Concurrent chemoradiotherapy with S-1 showed efficacy in T2N0 glottis carcinoma.
  • Further investigation of this treatment with long-term follow up results is warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Combinations. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487914.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


14. Lai FY, Zhang Q, Guo ZM, Zeng ZY, Li H, Yu WB, Yang CS: [Treatment and prognosis of stage IV glottic laryngeal cancer]. Ai Zheng; 2008 Jan;27(1):71-4
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of stage IV glottic laryngeal cancer].
  • BACKGROUND & OBJECTIVE: The prognosis of stage IV glottic cancer is poor.
  • This study was to explore the impacts of different treatment modalities, cervical lymph node status and surgical margin on the prognosis of stage IV glottic cancer.
  • METHODS: Clinical data of 88 patients with stage IV glottic cancer were reviewed.
  • The correlations of different treatment modalities, cervical lymph node status, and surgical margin to the prognosis of stage IV glottic cancer were analyzed.
  • There was no significant difference in survival rate among the patients received operation, operation plus postoperative radiotherapy, chemoradiotherapy, and operation plus chemotherapy (P=0.729).
  • CONCLUSIONS: N stage is the important prognostic factor for stage IV glottic cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Glottis / pathology. Laryngeal Neoplasms / therapy. Laryngectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184468.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Nur DA, Oguz C, Kemal ET, Ferhat E, Sülen S, Emel A, Münir K, Ann CS, Mehmet S: Prognostic factors in early glottic carcinoma implications for treatment. Tumori; 2005 Mar-Apr;91(2):182-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in early glottic carcinoma implications for treatment.
  • AIM: In this study we aimed to determine the prognostic factors affecting local control (LC) in limited glottic carcinoma treated with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Between June 1991 and December 2001, 114 patients with early squamous-cell carcinoma of the glottis were treated with definitive RT at our institution.
  • A median dose of 66 Gy (50-70.2) was given over a median period of 46 days (20-60).
  • The prognostic parameters analyzed for LC were T classification, anterior commissure involvement, total RT dose, and overall treatment time.
  • In 15 patients with local failure, salvage treatment consisted of partial laryngectomy in eight patients and total laryngectomy in five.
  • In one of the three patients with regional failure, salvage surgery was applied and the other two were given palliative chemotherapy because of unresectable disease.
  • Following salvage treatments, the ultimate five-year LC rate was 96.9% and the five-year larynx preservation rate was 91.1%.
  • Only one patient developed distant metastases and two patients died of laryngeal cancer.
  • CONCLUSION: In patients with early glottic carcinoma, T classification proved to be the only independent prognostic factor affecting LC after primary radiotherapy according to the results of this study.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948549.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Itoh Y, Fuwa N: Retrospective analysis: concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Radiat Med; 2006 May;24(4):277-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis: concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer.
  • PURPOSE: Treatment with conventional radiotherapy alone for local control of T2 glottic cancer (T2GC) is insufficient.
  • MATERIALS AND METHODS: We performed this combination therapy in a total of 11 consecutive patients with previously untreated invasive squamous cell carcinoma (T2GC).
  • Cisplatin was administered at 4 mg/m2/day and 5-FU at 200 mg/m2/day for 120 h, except during weekends, beginning on the day irradiation with a once-daily fraction at 2 Gy was started.
  • Grade 3 laryngitis was observed in four patients (36%), but none of these patients required interruption of treatment owing to acute laryngeal reactions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Neoplasms, Squamous Cell / drug therapy. Neoplasms, Squamous Cell / radiotherapy. Vocal Cords / drug effects. Vocal Cords / radiation effects
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1999 Jul;59(8):395-401 [10459284.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):1-7 [9210702.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1009-13 [10192348.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Oct;24(13):1892-900 [9350233.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):541-8 [9486602.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jan;124(1):35-9 [11228449.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1709-11 [12820445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Head Neck. 1999 Mar;21(2):116-23 [10091979.001]
  • [Cites] Head Neck. 2004 Feb;26(2):127-35 [14762881.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Int J Clin Oncol. 2000 Feb;5(1):18-21 [20563692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):1-12 [10758302.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):230-4 [12040278.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • (PMID = 16958401.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Alieva SB, Tkachev SI, Romanov IS, Zaderenko IA, Tiuliandin SA: [Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity]. Vopr Onkol; 2010;56(5):597-602
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity].
  • Two modalities of chemoradiotherapy for locally advanced squamous cell cancer of oro-hypopharynx and oral cavity were compared in the treatment of 34 patients.
  • Five-year survival after cisplatin, 5-FU, taxotere, and carboplatin plus irradiation with TTD of 68-72 Gy (group 1) was 59.5% versus 13.8% without taxotere (group 2).
  • Post-therapeutic complication stage III-IV was 57.8% (group 1) and 48% (group 2).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis. Laryngeal Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Platinum Compounds / administration & dosage. Radiotherapy, Adjuvant / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137242.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Hua H, Liu Q, Han Z, Chen J, Li F, Ding H: [The study on the occult metastases to cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Sep;15(9):391-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The study on the occult metastases to cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx].
  • OBJECTIVE: To study the metastastic regularity of cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx, which will provide some theoretical basis for surgeon to use selective neck dissection (SND) in some patients with carcinoma above.
  • These patients weren't given any treatment (radiotherapy or chemotherapy or surgery in neck) before surgery.
  • There were no occult metastases to cervical lymph node among 9 patients with glottic cancer.
  • CONCLUSION: The study further prove that metastases to cervical lymph node mainly occur in the ipsilateral level II and level III among patients with carcinoma of the larynx and hypopharynx.
  • According to the risks of occurring occult metastases to cervical lymph node, we suggest applying to ipsilateral or bilateral SND (level II and level III be dissected) among patients with carcinoma of the larynx and hypopharynx which staged T2-T4 N0M0 clinically.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12541884.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Tian WD, Zeng ZY, Chen FJ, Wu GH, Guo ZM, Zhang Q: [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma]. Ai Zheng; 2006 Jan;25(1):80-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
  • BACKGROUND & OBJECTIVE: Laryngeal squamous cell carcinoma (LSCC) is a common malignancy of the head and neck.
  • Stage I-II LSCC patients have a favorable prognosis after operation or radiotherapy, but the curative effect and prognosis of stage III-IV LSCC are not satisfying, and its treatment is also controversial.
  • This study was to summarize our experience in treating stage III-IV LSCC patients, evaluate the treatment results, and seek more reasonable therapeutic modality.
  • Of the 202 patients, 64 received surgery alone, 83 received surgery and preoperative or postoperative radiotherapy, 41 received radiotherapy, and 14 received chemotherapy.
  • RESULTS: The 5- and 10-year overall survival rates of the 202 patients was (42.12+/-3.62)% and (33.20+/-4.32)%, and the median survival time was 48.5 months.
  • The 5-year survival rates were 61.07% in glottic carcinoma group and 26.07% in supraglottic carcinoma group, and were 53.41% in surgery alone group, 51.04% in surgery plus radiotherapy group, 18.33% in radiotherapy group and 7.14% in chemotherapy group.
  • CONCLUSIONS: Surgery, especially total laryngectomy, is the major treatment modality for stage III-IV LSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405756.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Mercante G, Bacciu A, Banchini L, Moretto E, Oretti G, Ferri T: Salvage surgery after radiation failure in squamous cell carcinoma of the larynx. B-ENT; 2005;1(3):107-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after radiation failure in squamous cell carcinoma of the larynx.
  • AIM AND BACKGROUND: To investigate patients treated with radiotherapy (RT) for laryngeal squamous cell carcinoma (SCC) in order to estimate the recurrence rate and treatment used as salvage surgery.
  • The survival rate in the group of patients treated with salvage surgery was compared to that of patients who had chemotherapy rather than surgery or who refused any treatment.
  • All of them underwent RT as primary treatment.
  • The global and actuarial survival rate was 20% after three years and 0% after five years in the group of patients who received chemotherapy rather than surgery or who refused any kind of treatment.
  • CONCLUSION: The RT seems to play an important role in the loco-regional control of laryngeal SCC (especially in glottic T1).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255494.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


21. Tsuji H, Nagata M, Inoue T, Minami T, Iwai H, Ohnishi S, Yukawa H, Ogura M, Yamashita T, Nagata K: [Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma]. Gan To Kagaku Ryoho; 2006 Jun;33 Suppl 1:163-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
  • We conducted a phase I study to determine a recommended dose (RD) of S-1 for chemo-radiotherapy consisting of S-1+ radiotherapy for T 2 N 0 larynx cancer.
  • The method of administration used to assess the RD was irradiation with 2 Gy/day for 5 days a week until a total dose of 60 Gy, and concomitant administration of S-1 once a day for 2 weeks beginning on the day therapy was started followed by 2 weeks off the drug and 2 weeks on the drug with the dose escalating from S-1 60 mg/body/day (level 1) to 80 mg/body/day (level 2), and then to 100 mg/body/day (level 3).
  • 4 patients developed an adverse event of grade 3 radiation dermatitis which became a dose-limiting toxicity (DLT) at level 3.
  • We then concluded that 100 mg/body/day was the maximum tolerated dose (MTD) of S-1 and decided that the RD of S-1 was 80 mg/body/day.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Combined Modality Therapy. Deglutition Disorders / etiology. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Male. Maximum Tolerated Dose. Middle Aged. Radiation Injuries / etiology. Radiodermatitis / etiology. Radiotherapy Dosage. Stomatitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897995.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial, Phase I; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


22. Nakayama M, Hayakawa K, Okamoto M, Niibe Y, Ishiyama H, Kotani S: Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer. Jpn J Clin Oncol; 2010 Oct;40(10):921-6
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
  • OBJECTIVE: A Phase I/II study of S-1 combined radiation therapy was conducted in patients with Stage II (T2N0) glottic cancer.
  • Radiation therapy was administered in 2-Gy daily (total 60-Gy) standard fractionation.
  • All 26 patients completed radiation therapy without delay.
  • One patient developed a local recurrence 28 months after the treatment.
  • CONCLUSIONS: The use of S-1 at 80 mg/m(2) per day in a split-course with 1-week rest during the course of radiation therapy was safe and effective for Stage II glottic cancer.
  • The treatment strategy employing orally available S-1 proved to be beneficial over the conventional injection of antitumor agents for maintaining the patients' quality of life.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Oxonic Acid / therapeutic use. Radiotherapy / methods. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Anemia / etiology. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Follow-Up Studies. Glottis / drug effects. Glottis / pathology. Glottis / radiation effects. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Nausea / etiology. Neutropenia / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495190.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


23. Imauchi Y, Ito K, Takasago E, Nibu K, Sugasawa M, Ichimura K: Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg; 2002 Jan;126(1):63-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx.
  • OBJECTIVE: Stomal recurrence after total laryngectomy is one of the most serious issues in the management of laryngeal carcinoma.
  • The management of stomal recurrence, including chemotherapy, radiotherapy, and surgery, has been reported as unsatisfactory.
  • STUDY DESIGN AND SETTING: From 1985 to 1995, 69 patients underwent total laryngectomy for the treatment of laryngeal cancer at the University of Tokyo Hospital.
  • RESULTS: Stomal recurrence developed in 6 of 69 patients who underwent total laryngectomy for laryngeal carcinoma.
  • CONCLUSION: Intensive follow-up should be performed for patients with glottic carcinoma who had preoperative tracheotomy, paratracheal lymph node metastasis, or both to detect stomal recurrence at an early stage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Risk Factors. Salvage Therapy. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / epidemiology. Tracheal Neoplasms / secondary. Tracheotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11821768.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Yoshizaki T, Kondo S, Wakisaka N, Murono S, Kitagawa N, Tsuji A, Nakashima M, Sanada J, Matsui O: Concurrent intra-arterial chemotherapy and radiotherapy for advanced laryngeal cancer. Ann Otol Rhinol Laryngol; 2009 Mar;118(3):172-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent intra-arterial chemotherapy and radiotherapy for advanced laryngeal cancer.
  • METHODS: Forty-three patients with advanced laryngeal cancer were treated with 2 courses of intra-arterial cisplatin infusion (100 mg per body) during 40-Gy irradiation.
  • The patients with obvious residual disease received chemotherapy during the sequential irradiation.
  • Thirty-four patients were alive (80% of the supraglottic cases and 87.5% of the glottic cases).
  • Local control was achieved in 27 patients (67.5% of the 11 glottic cases and 64.0% of the supraglottic cases).
  • The glottic cohort showed better progression-free survival rates than did the supraglottic cohort (68.8% and 45.0%, respectively; p = 0.019).
  • One patient required tracheostomy 3 months after the completion of the treatment protocol.
  • CONCLUSIONS: Concurrent chemoradiotherapy with a reduced dose of intra-arterial cisplatin is feasible for patients with advanced glottic cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Cohort Studies. Disease-Free Survival. Dose Fractionation. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374147.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB: T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am J Clin Oncol; 2007 Apr;30(2):181-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience.
  • PURPOSE: The purpose of this study was to report the outcomes after external-beam radiotherapy (RT) for selected T3 and T4 vocal cord squamous cell carcinomas.
  • METHODS AND MATERIALS: One hundred nine patients with previously untreated T3 and T4 squamous cell carcinomas of the glottic larynx were treated with curative intent in this Institutional Review Board-approved outcome study using continuous-course RT alone (106 patients) or followed by a planned neck dissection (3 patients) between September 1966 and June 2002.
  • Patients selected for such treatment had relatively low-volume, unilateral disease.
  • RESULTS: The 5-year outcomes after treatment were: local control for stage T3 and T4, 78% and 81%; locoregional control for AJCC stage III and IVa, 62% and 78%; distant metastasis-free survival for AJCC stage III and IVa, 97% and 100%; cause-specific survival for AJCC stage III and IVa, 84% and 87%; and overall survival for AJCC stage III and IVa, 52% and 67%, respectively.
  • Local control and ultimate cure probabilities will hopefully improve further with the addition of concomitant chemotherapy to RT for larger tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Vocal Cords

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414468.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Xu C, Dong P, Xu H: [The therapeutic outcomes of surgery on senile patients with laryngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Aug;21(15):688-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The therapeutic outcomes of surgery on senile patients with laryngeal carcinoma].
  • OBJECTIVE: To investigate the therapeutic outcomes of Laryngectomy and prognostic factors in senile patients with laryngeal carcinoma.
  • METHOD: A retrospective study of long-term therapeutic outcomes was performed on 110 patients with laryngeal carcinoma over 65, treated mainly by surgery, from 1990 to 2005.
  • Different kinds of operations were as follows: cordectomy(1 case) or stripping (2 cases) by suspended laryngoscope, laryngofissure (4 cases), vertical partial laryngectomy without tracheotomy (8 cases), vertical partial laryngectomy (8 cases), extended vertical partial laryngectomy (1 case), horizontal laryngectomy (4 cases), subtotal laryngectomy (4 cases), cricohyoidoepiglottopexy (30 cases), Arslan's procedure (8 cases), and total laryngectomy (40 cases).
  • Forty-eight patients were treated with preoperative or postoperative radiotherapy, and five patients were treated with induction chemotherapy followed by radiotherapy.
  • Well-differentiation, surgery alone, node-negative, glottic carcinoma, early stage, partial laryngectomy, non-recurrence and male were favorable prognostic factors with univariate analysis (P < 0. 05).
  • Well-differentiation and surgery without combined therapy were also favorable prognostic factors with multivariate analysis.
  • CONCLUSION: Conservation laryngectomy was an efficient method to treat senile patients with laryngeal carcinoma.
  • Combined therapy should better not be adopted to patients with negative surgical margins.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Laryngectomy / methods. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969520.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Maeda Y, Fujishiro Y, Chihara Y, Kawanabe W, Fukaya T: [A case of pulmonary metastases from laryngeal cancer showing a complete response to chemotherapy with docetaxel]. Gan To Kagaku Ryoho; 2004 Jan;31(1):75-7
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary metastases from laryngeal cancer showing a complete response to chemotherapy with docetaxel].
  • The patient was a 61-year-old man who had undergone laryngectomy and irradiation for laryngeal cancer (glottic type: T3N0M0).
  • More than 2 years later after the first course of therapy, pulmonary metastases involved in the left lower area were revealed by lung CT.
  • The divided TXT therapy (20 mg, 3 times, and 40 mg, 3 times) was carried out without any sequelae.
  • This consecutive therapy resulted in complete disappearance of the metastases on follow-up CT.
  • It is suggested that divided TXT therapy has potential as a new treatment modality for distant metastases of H and N cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Laryngeal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Taxoids / administration & dosage
  • [MeSH-minor] Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750325.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


28. Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, Fu KK: Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1172-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
  • PURPOSE: To review the UCSF-SUH experience in the treatment of advanced T3--4 laryngeal carcinoma and to evaluate the different factors affecting locoregional control and survival.
  • METHODS AND MATERIALS: We reviewed the records of 223 patients treated for T3--4 squamous cell carcinoma of the larynx between October 1, 1957, and December 1, 1999.
  • The primary site was glottic in 122 and supraglottic in 101 patients.
  • Surgery was the primary treatment modality in 161 patients, of which 134 had postoperative radiotherapy (RT), 11 had preoperative RT, 7 had surgery followed by RT and chemotherapy (CT), and 9 had surgery alone.
  • Significant prognostic factors for LRC on univariate analysis were primary site, N stage, overall stage, the lowest hemoglobin (Hgb) level during RT, and treatment modality.
  • Significant prognostic factors for OS on univariate analysis were: primary site, age, overall stage, T stage, N stage, lowest Hgb level during RT, and treatment modality.
  • Correcting the Hbg level before and during treatment should be investigated in future clinical trials as a way of improving therapeutic outcome in patients with advanced laryngeal carcinomas.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. California / epidemiology. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Hemoglobins / analysis. Humans. Laryngectomy / adverse effects. Life Tables. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483326.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Basseri B, Conklin JL, Mertens RB, Lo SK, Bellack GS, Shaye OA: Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature. Dis Esophagus; 2009;22(4):E1-5
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic gastric mucosa (inlet patch) in a patient with laryngopharyngeal reflux (LPR) and laryngeal carcinoma: a case report and review of literature.
  • Herein, we present the first reported case of inlet patch associated with laryngeal carcinoma.
  • A 33-year-old female with long-standing asthma and presumed gastroesophageal reflux developed laryngeal cancer at age 22 years that was treated with concomitant radiation and induction chemotherapy.
  • These symptoms continued despite two Nissen fundoplications, glottic web division, and optimal medical management.
  • Biopsies showed columnar mucosa (predominantly gastric cardiac/fundic type) consistent with inlet patch, with focal intestinal metaplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473208.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


30. Kada S, Hirano S, Tateya I, Kitamura M, Ishikawa S, Kanda T, Asato R, Tanaka S, Ito J: Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University. Acta Otolaryngol Suppl; 2010 Nov;(563):68-73
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University.
  • OBJECTIVE: The therapeutic outcomes of 33 cases with advanced laryngeal cancer treated at Kyoto University Hospital between 2000 and 2008 were reviewed.
  • All tumors were squamous cell carcinoma, arising at the glottis in 21 cases and the supraglottis in 12 cases.
  • Most glottic cancers (90.5%) and supraglottic cancers (83.3%) were classified as T3 or T4.
  • Total laryngectomy with neck dissection was performed in the treatment of T3 or T4 cases.
  • Two cases of T2 cancers were treated by radiotherapy (66-72 Gy) with neck dissection, and one case of T2 cancer was treated by radiotherapy (66 Gy).
  • RESULTS: Five-year overall survival rates for stage III of glottic cancer, stage IV of glottic cancer, stage III of supraglottic cancer, and stage IV of supraglottic cancer were 100%, 40.9%, 100%, and 24.2%, respectively.
  • Five-year disease-specific survival rates for stage III of glottic cancer, stage IV of glottic cancer, stage III of supraglottic cancer, and stage IV of supraglottic cancer were 100%, 56.3%, 100%, and 28.1%, respectively.
  • Regional lymph node recurrence occurred in two cases- one patient with glottic cancer and one with supraglottic cancer.
  • Both of them died of disease despite undergoing chemotherapy.
  • One case initially had lung metastasis, and post-treatment distant metastasis occurred in the lung in four cases, in the skin in one, and in multiple organs in one case.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Female. Hospitals, University. Humans. Japan. Laryngectomy. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879822.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Byard RW, Gilbert JD: Narcotic administration and stenosing lesions of the upper airway--a potentially lethal combination. J Clin Forensic Med; 2005 Feb;12(1):29-31
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 2: A 48-year-old woman with severe narrowing of her glottic inlet from recurrent squamous cell carcinoma and an intravenous drug taking history was found dead at her home.
  • At autopsy there was evidence of recent and remote intravenous drug administration with marked narrowing of the glottis due to a recurrent tumor with a blood morphine level of 0.48 mg/L.
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Epstein-Barr Virus Infections / complications. Fatal Outcome. Female. Forensic Pathology. Glottis / pathology. Humans. Middle Aged. Migraine Disorders / drug therapy. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Neoplasm Invasiveness. Substance Abuse, Intravenous / complications. Tonsillitis / virology

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763687.001).
  • [ISSN] 1353-1131
  • [Journal-full-title] Journal of clinical forensic medicine
  • [ISO-abbreviation] J Clin Forensic Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine
  •  go-up   go-down






Advertisement